<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03344640</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457X2201</org_study_id>
    <secondary_id>2017-003099-30</secondary_id>
    <nct_id>NCT03344640</nct_id>
  </id_info>
  <brief_title>Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II, 24-week Study Investigating the Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy Refractory to Oral NSAIDs/Acetaminophen, Physiotherapy or Corticosteroid Injections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a randomized, double-blind, placebo-controlled, multi-center, Phase II study of s.c.&#xD;
      secukinumab 300 mg in 98 randomized patients with overuse rotator-cuff tendinopathy without&#xD;
      systemic inflammatory disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, double-blind, placebo-controlled, multi-center, Phase II study of s.c.&#xD;
      secukinumab 300 mg in 98 randomized patients with overuse rotator-cuff tendinopathy without&#xD;
      systemic inflammatory disease and refractory to NSAIDs/acetaminophen, physiotherapy or&#xD;
      corticosteroids.&#xD;
&#xD;
      The study consisted of a 4-week screening period, a 2-week run-in period, a 12-week treatment&#xD;
      period and a 12-week follow-up period after last treatment. The population consisted of&#xD;
      patients with unilateral overuse (non-systemic inflammatory) shoulder tendinopathy, 18 - 65&#xD;
      years of age.&#xD;
&#xD;
      Safety assessments included physical examinations, ECGs, vital signs, standard clinical&#xD;
      laboratory evaluations (hematology, blood chemistry, and urinalysis), adverse event and&#xD;
      serious adverse event monitoring.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Actual">October 17, 2019</completion_date>
  <primary_completion_date type="Actual">August 2, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patients and investigators were blinded until EOS. Sponsor was blinded until after the analysis of the primary endpoint at week 14.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Score at Week 14 in All Patients - Statistical Analysis Results of Total WORC Scores at Week 14</measure>
    <time_frame>Week 14 (Day 99)</time_frame>
    <description>WORC PRO score at week 14. The WORC Index consists of 21 items divided into 5 Domains: Physical Symptoms (6 items), Sport/Recreation (4 items), Work Function (4 items), Lifestyle Function (4 items) and Emotional Function (3 items). The total scores and sub scores used were the percentages of the normal scores with 0 being worst and 100 being best.&#xD;
All Patients - Statistical analysis results of WORC scores at Week 14</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Scores Over Time in All Patients</measure>
    <time_frame>Days 15, 29, 57, 85, 127, and End of Study</time_frame>
    <description>WORC score at Days 15, 29, 57, 85, 127, and End of Study (day 169). The scale range for WORC total score is 0-100, 0 being the worst possible outcome (highly symptomatic patient) and 100 being the best possible outcome (asymptomatic patient)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability of Arm, Shoulder and Hand Questionnaire Score (QuickDASH) Over Time</measure>
    <time_frame>Days 15, 29, 57, 85, 99, 127, and End of Study</time_frame>
    <description>Patient Reported Outcome: Disability of Arm, Shoulder and Hand (QuickDASH) This questionnaire asks about symptoms as well participant's ability to do certain activities - ranging from 1 (No difficulty) to 5 (Unable).&#xD;
The scale range for QuickDASH total score is 0-100, 0 being the best possible outcome and 100 being the worst possible outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American Shoulder and Elbow Surgeons (ASES) Score Over Time</measure>
    <time_frame>Days 15, 29, 57, 85, 99, 127, and End of Study</time_frame>
    <description>Patient Reported Outcome: American Shoulder and Elbow Surgeons Shoulder Evaluation Form (ASES) score is self-administered and has 17 questions in the areas of shoulder symptoms and functions. The ASES total score ranges from 0 to 100 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Your Health Today Score Over Time</measure>
    <time_frame>Days 15, 29, 57, 85, 99, 127, and End of Study</time_frame>
    <description>Patient Reported Outcome: Statistical analysis results of EQ-5D-5L for Your health Today questionnaire, which reflects how good or bad the subjets Health is on a scale from 0 (worst health) to 100 (best health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L Index Score Over Time</measure>
    <time_frame>Days 15, 29, 57, 85, 99, 127 and End of Study</time_frame>
    <description>Patient Reported Outcome: Statistical analysis results of EQ-5D-5L Index score, which contains 5 items to assess Health Status (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression). Overall scores range from 0 to 1 with lower scores representing a higher level of dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score Over Time Using a VAS Scale</measure>
    <time_frame>Days 15, 29, 57, 85, 99, 127 and End of Study</time_frame>
    <description>Pain intensity is assessed by a Visual Analog Scale (VAS) which is measured on a 100mm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain&quot;.&#xD;
The scale range for pain score is 0-100, 0 being the best possible outcome (no pain) and 100 being the worst possible outcome (worst pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment (PGA) Score Over Time Using a VAS Scale</measure>
    <time_frame>Days 15, 29, 57, 85, 99, 127 and End of Study</time_frame>
    <description>The patient's global assessment of disease activity is performed using a 100 mm Visual Analog Scale (VAS) ranging from &quot;no activity&quot; to &quot;most active&quot; in the last 24 hours.&#xD;
The scale range for PGA score is 0-100, 0 being the best possible outcome (no disease activity) and 100 being the worst possible outcome (maximal disease activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment (PhGA) Score Using a VAS Scale Over Time</measure>
    <time_frame>Days 15, 29, 57, 85, 99, 127 and End of Study</time_frame>
    <description>Physician global assessment (PhGA) score using a VAS scale (considering the last 24 hours).&#xD;
The scale range for PhGA score is 0-100, 0 being the best possible outcome (no disease activity) and 100 being the worst possible outcome (maximal disease activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Cmin</measure>
    <time_frame>Days 1, 29, 85 and EoS (End of Study)</time_frame>
    <description>Mean trough concentrations&#xD;
Cmin is a pharmacokinetics term for the minimum blood plasma concentration reached by a drug prior to administration of a second dose (mass/volume)&#xD;
Serum trough concentrations of secukinumab 300 mg group was measured at Days 1, 29, 85 and EoS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Assessment - Treatment Emergent ADAs</measure>
    <time_frame>Day 1 and EoS</time_frame>
    <description>Number of Participants with Treatment emergent Anti-secukinumab antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Tendinosis Grade Score 1, 2 or 3 Measured by Magnetic Resonance Imaging (MRI) Sein Scores</measure>
    <time_frame>Baseline and Day 99</time_frame>
    <description>Assessment of structural changes in the rotator cuff tendinopathy over time&#xD;
The MRI Sein score was used to grade supraspinatus tendinosis using a modified 4-point scale from 0 to 3 and changes in grading over time were captured in the shift table. Grade 0 is normal, grade 1 is mild, Grade 2 is moderate and grade 3 is marked tendinosis.&#xD;
In this Sein score assessment, only data from Day 99 and baseline could be compared, as only those two time points were double read and adjudicated in case the 2 readers had different results. At any other time-points (Day 57 and EOS), images were assessed only by one reader and thus could not be compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Tendinopathy</condition>
  <arm_group>
    <arm_group_label>secukinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AIN457 300 mg subcutaneously (s.c.) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneously for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>secukinumab</intervention_name>
    <description>AIN457 300 mg subcutaneously for 12 weeks</description>
    <arm_group_label>secukinumab</arm_group_label>
    <other_name>AIN457</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match AIN457 subcutaneously for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or non-pregnant, non-lactating female patients 18 to 65 years of age at&#xD;
             randomization&#xD;
&#xD;
          2. Presence of unilateral rotator cuff tendinopathy with:&#xD;
&#xD;
               1. Symptoms present ≥6 weeks, but &lt;12 months prior to randomization&#xD;
&#xD;
               2. Tendinopathy with no more than a 50% tear as established by ultrasound at&#xD;
                  screening (historic data acceptable if not older than 3 months) and MRI at&#xD;
                  baseline: Sein MRI tendinopathy scoring system grade I-III; with no tear or&#xD;
                  partial tear [maximum 50% tendon thickness (Bauer tendon thickness score maximum&#xD;
                  2); AP length maximum 10 mm (Bauer tendon length score max 2)]. Maximum 50% of&#xD;
                  patients with partial tear&#xD;
&#xD;
               3. Pain in the affected shoulder (at rest or on movement) on at least 3 days out of&#xD;
                  7 days in the past week prior to baseline and a score of ≥4 out of 10 on a VAS&#xD;
                  pain scale&#xD;
&#xD;
               4. Positive &quot;Painful Arc Test&quot; on examination and/or nightly pain in the affected&#xD;
                  shoulder on at least 4 out of 7 days in the past week prior to baseline&#xD;
&#xD;
          3. The rotator-cuff tendinopathy must have been refractory to standard treatment,&#xD;
             including NSAIDs and physiotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Rheumatologic, inflammatory diseases, including but not limited to: PsA, AS and RA 2.&#xD;
        Previous shoulder surgery in affected shoulder 3. History of adhesive capsulitis/frozen&#xD;
        shoulder or calcification in the tendon (in affected or contralateral shoulder) confirmed&#xD;
        by X-Ray, historic X-Rays can be used if performed within 3 months of baseline 4.&#xD;
        Symptomatic osteoarthritis of the shoulder (gleno-humeral, acromioclavicular) (in affected&#xD;
        or contralateral shoulder confirmed by X-Ray, historic X-Rays can be used if performed&#xD;
        within 3 months of baseline 5. Neck conditions, including but not limited to cervical spine&#xD;
        syndrome, which in the opinion of the investigator, may explain the patient's symptoms 6.&#xD;
        Previous platelet rich plasma injections within the last 12 months prior to randomization&#xD;
        7. Previous treatment with any cell-depleting therapies including but not limited to anti-&#xD;
        CD20, investigational agents (e.g. Campath, anti-CD4, anti-CD5, anti-CD3, anti-CD19) 8.&#xD;
        Previous exposure to any biologic immunomodulating agents, including but not limited to&#xD;
        TNFalpha inhibitors (including, but not limited to adalimumab, infliximab), or biologics&#xD;
        targeting IL-17 (including, but not limited to secukinumab, ixekizumab or brodalumab) or&#xD;
        the IL-17 receptor within the last 12 months prior to baseline 9. Any&#xD;
        intraarticular/subacromial corticosteroid treatment within 8 weeks prior to randomization&#xD;
        and more than 3 injections for the current tendinopathy. Oral, intramuscular or i.v.&#xD;
        corticosteroid treatment within the last 12 months prior to randomization&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <state>Czech Republic</state>
        <zip>66250</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kolin</city>
        <state>Czech Republic</state>
        <zip>280 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leiden</city>
        <zip>2333 CL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=687</url>
    <description>A Plain Language Trial Summary is available on novartisclinicaltrials.com</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <results_first_submitted>October 16, 2020</results_first_submitted>
  <results_first_submitted_qc>November 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 9, 2020</results_first_posted>
  <disposition_first_submitted>February 17, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>November 13, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 9, 2020</disposition_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overuse tendinopathy</keyword>
  <keyword>shoulder</keyword>
  <keyword>rotator cuff</keyword>
  <keyword>IL-17A-Ab</keyword>
  <keyword>AIN457X</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tendinopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT03344640/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT03344640/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of all patients randomized (N= 98; 100%) in the study, a total of 96 patients (98%) were dosed (49 patients in the secukinumab 300 mg group and 47 patients in the placebo group)</recruitment_details>
      <pre_assignment_details>2 patients were not dosed, one patient decided to discontinue on Day 1 due to a common cold and one patient was a run-in failure</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Secukinumab</title>
          <description>AIN457 300 mg subcutaneously (s.c.)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo s.c.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up Epoch</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety analysis set (SAS) included all subjects that received any study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Secukinumab</title>
          <description>AIN457 300 mg subcutaneously (s.c.)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo s.c.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Demographic summary (Safety analysis set)</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.8" spread="11.51"/>
                    <measurement group_id="B2" value="49.1" spread="10.56"/>
                    <measurement group_id="B3" value="46.9" spread="11.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>41.7% of participants were female, and 58.3% were male</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>1% Asian, 4.2% Black or African American, 91.7% White, 1% Unknown, 2.1% Other</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Score at Week 14 in All Patients - Statistical Analysis Results of Total WORC Scores at Week 14</title>
        <description>WORC PRO score at week 14. The WORC Index consists of 21 items divided into 5 Domains: Physical Symptoms (6 items), Sport/Recreation (4 items), Work Function (4 items), Lifestyle Function (4 items) and Emotional Function (3 items). The total scores and sub scores used were the percentages of the normal scores with 0 being worst and 100 being best.&#xD;
All Patients - Statistical analysis results of WORC scores at Week 14</description>
        <time_frame>Week 14 (Day 99)</time_frame>
        <population>Pharmacodynamic (PD) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>AIN457 300 mg subcutaneously (s.c.)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c.</description>
          </group>
        </group_list>
        <measure>
          <title>The Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Score at Week 14 in All Patients - Statistical Analysis Results of Total WORC Scores at Week 14</title>
          <description>WORC PRO score at week 14. The WORC Index consists of 21 items divided into 5 Domains: Physical Symptoms (6 items), Sport/Recreation (4 items), Work Function (4 items), Lifestyle Function (4 items) and Emotional Function (3 items). The total scores and sub scores used were the percentages of the normal scores with 0 being worst and 100 being best.&#xD;
All Patients - Statistical analysis results of WORC scores at Week 14</description>
          <population>Pharmacodynamic (PD) Analysis Set</population>
          <units>Scores on a scale</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.00" lower_limit="30.10" upper_limit="43.90"/>
                    <measurement group_id="O2" value="37.77" lower_limit="30.40" upper_limit="45.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All Patients at day 99</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.875</p_value>
            <method>LS mean</method>
            <method_desc>LS mean change from baseline in WORC total percentage score</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.77</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.84</ci_lower_limit>
            <ci_upper_limit>7.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Scores Over Time in All Patients</title>
        <description>WORC score at Days 15, 29, 57, 85, 127, and End of Study (day 169). The scale range for WORC total score is 0-100, 0 being the worst possible outcome (highly symptomatic patient) and 100 being the best possible outcome (asymptomatic patient)</description>
        <time_frame>Days 15, 29, 57, 85, 127, and End of Study</time_frame>
        <population>PD Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>AIN457 300 mg subcutaneously (s.c.)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c.</description>
          </group>
        </group_list>
        <measure>
          <title>The Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Scores Over Time in All Patients</title>
          <description>WORC score at Days 15, 29, 57, 85, 127, and End of Study (day 169). The scale range for WORC total score is 0-100, 0 being the worst possible outcome (highly symptomatic patient) and 100 being the best possible outcome (asymptomatic patient)</description>
          <population>PD Analysis Set</population>
          <units>Scores on a scale</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.39" lower_limit="6.99" upper_limit="17.79"/>
                    <measurement group_id="O2" value="8.42" lower_limit="2.66" upper_limit="14.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.35" lower_limit="16.38" upper_limit="28.32"/>
                    <measurement group_id="O2" value="19.49" lower_limit="13.11" upper_limit="25.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.74" lower_limit="22.19" upper_limit="35.29"/>
                    <measurement group_id="O2" value="30.11" lower_limit="23.08" upper_limit="37.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.86" lower_limit="28.18" upper_limit="41.53"/>
                    <measurement group_id="O2" value="33.48" lower_limit="26.35" upper_limit="40.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.86" lower_limit="34.96" upper_limit="48.77"/>
                    <measurement group_id="O2" value="38.50" lower_limit="31.12" upper_limit="45.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.41" lower_limit="36.21" upper_limit="50.61"/>
                    <measurement group_id="O2" value="40.97" lower_limit="33.27" upper_limit="48.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All patientts at day 15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.190</p_value>
            <method>LS mean</method>
            <method_desc>LS mean change from baseline in WORC total percentage score</method_desc>
            <param_type>Difference and 90% CI versus placebo</param_type>
            <param_value>3.97</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>8.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All patients at day 29</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference and 90% CI versus placebo</param_type>
            <param_value>3.97</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.39</ci_lower_limit>
            <ci_upper_limit>9.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All patients at day 57</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.761</p_value>
            <method>LS Mean</method>
            <method_desc>LS mean change from baseline in WORC total percentage score</method_desc>
            <param_type>Difference and 90% CI versus placebo</param_type>
            <param_value>0.761</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.81</ci_lower_limit>
            <ci_upper_limit>6.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All patients at day 85</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.765</p_value>
            <method>LS Mean</method>
            <method_desc>LS mean change from baseline in WORC total percentage score</method_desc>
            <param_type>Difference and 90% CI versus placebo</param_type>
            <param_value>0.765</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.27</ci_lower_limit>
            <ci_upper_limit>9.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All patients at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.491</p_value>
            <method>LS Mean</method>
            <method_desc>LS mean change from baseline in WORC total percentage score</method_desc>
            <param_type>Difference and 90% CI versus placebo</param_type>
            <param_value>0.491</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.73</ci_lower_limit>
            <ci_upper_limit>11.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All patients at end of study</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.639</p_value>
            <method>LS Mean</method>
            <method_desc>LS mean change from baseline in WORC total percentage score</method_desc>
            <param_type>Difference and 90% CI versus placebo</param_type>
            <param_value>2.44</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.19</ci_lower_limit>
            <ci_upper_limit>11.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disability of Arm, Shoulder and Hand Questionnaire Score (QuickDASH) Over Time</title>
        <description>Patient Reported Outcome: Disability of Arm, Shoulder and Hand (QuickDASH) This questionnaire asks about symptoms as well participant's ability to do certain activities - ranging from 1 (No difficulty) to 5 (Unable).&#xD;
The scale range for QuickDASH total score is 0-100, 0 being the best possible outcome and 100 being the worst possible outcome</description>
        <time_frame>Days 15, 29, 57, 85, 99, 127, and End of Study</time_frame>
        <population>PD Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>AIN457 300 mg subcutaneously (s.c.)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c.</description>
          </group>
        </group_list>
        <measure>
          <title>Disability of Arm, Shoulder and Hand Questionnaire Score (QuickDASH) Over Time</title>
          <description>Patient Reported Outcome: Disability of Arm, Shoulder and Hand (QuickDASH) This questionnaire asks about symptoms as well participant's ability to do certain activities - ranging from 1 (No difficulty) to 5 (Unable).&#xD;
The scale range for QuickDASH total score is 0-100, 0 being the best possible outcome and 100 being the worst possible outcome</description>
          <population>PD Analysis Set</population>
          <units>Scores on a scale</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.64" lower_limit="-16.14" upper_limit="-7.14"/>
                    <measurement group_id="O2" value="-8.23" lower_limit="-13.02" upper_limit="-3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.31" lower_limit="-23.20" upper_limit="-13.41"/>
                    <measurement group_id="O2" value="-16.95" lower_limit="-22.18" upper_limit="-11.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.43" lower_limit="-27.55" upper_limit="-17.30"/>
                    <measurement group_id="O2" value="-24.01" lower_limit="-29.49" upper_limit="-18.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.14" lower_limit="-33.55" upper_limit="-22.73"/>
                    <measurement group_id="O2" value="-27.22" lower_limit="-32.98" upper_limit="-21.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.45" lower_limit="-34.72" upper_limit="-24.19"/>
                    <measurement group_id="O2" value="-30.69" lower_limit="-36.30" upper_limit="-25.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.86" lower_limit="-38.26" upper_limit="-27.46"/>
                    <measurement group_id="O2" value="-31.99" lower_limit="-37.75" upper_limit="-26.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.89" lower_limit="-39.27" upper_limit="-28.50"/>
                    <measurement group_id="O2" value="-35.40" lower_limit="-41.13" upper_limit="-29.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis results of QuickDASH total score (PD Analysis Set) at day 99</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.735</p_value>
            <p_value_desc>Difference and 90% CI versus placebo</p_value_desc>
            <method>LS Mean</method>
            <method_desc>LS mean change from baseline in QuickDASH total score</method_desc>
            <param_type>Difference and 90% CI versus Placebo</param_type>
            <param_value>1.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.81</ci_lower_limit>
            <ci_upper_limit>7.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis results of QuickDASH total score (PD analysis set) at End of Study</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.689</p_value>
            <method>LS Mean</method>
            <method_desc>LS mean change from baseline in QuickDASH total score</method_desc>
            <param_type>Difference and 90% CI versus Placebo</param_type>
            <param_value>1.51</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.76</ci_lower_limit>
            <ci_upper_limit>7.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American Shoulder and Elbow Surgeons (ASES) Score Over Time</title>
        <description>Patient Reported Outcome: American Shoulder and Elbow Surgeons Shoulder Evaluation Form (ASES) score is self-administered and has 17 questions in the areas of shoulder symptoms and functions. The ASES total score ranges from 0 to 100 (best).</description>
        <time_frame>Days 15, 29, 57, 85, 99, 127, and End of Study</time_frame>
        <population>PD Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>AIN457 300 mg subcutaneously (s.c.)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c.</description>
          </group>
        </group_list>
        <measure>
          <title>American Shoulder and Elbow Surgeons (ASES) Score Over Time</title>
          <description>Patient Reported Outcome: American Shoulder and Elbow Surgeons Shoulder Evaluation Form (ASES) score is self-administered and has 17 questions in the areas of shoulder symptoms and functions. The ASES total score ranges from 0 to 100 (best).</description>
          <population>PD Analysis Set</population>
          <units>Scores on a scale</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.66" lower_limit="3.98" upper_limit="13.33"/>
                    <measurement group_id="O2" value="5.26" lower_limit="0.26" upper_limit="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.53" lower_limit="12.35" upper_limit="22.71"/>
                    <measurement group_id="O2" value="14.37" lower_limit="8.82" upper_limit="19.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.15" lower_limit="18.34" upper_limit="29.96"/>
                    <measurement group_id="O2" value="22.56" lower_limit="16.31" upper_limit="28.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.50" lower_limit="24.51" upper_limit="36.50"/>
                    <measurement group_id="O2" value="26.97" lower_limit="20.51" upper_limit="33.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.29" lower_limit="25.28" upper_limit="37.31"/>
                    <measurement group_id="O2" value="27.79" lower_limit="21.33" upper_limit="34.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.92" lower_limit="28.80" upper_limit="41.05"/>
                    <measurement group_id="O2" value="32.94" lower_limit="26.33" upper_limit="39.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.29" lower_limit="30.97" upper_limit="43.62"/>
                    <measurement group_id="O2" value="36.15" lower_limit="29.33" upper_limit="42.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis results of ASES total score (PD analysis) at day 99</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.411</p_value>
            <method>LS Mean</method>
            <method_desc>LS mean change from baseline in ASES total percentage score</method_desc>
            <param_type>Difference and 90% CI vesus placebo</param_type>
            <param_value>3.50</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.54</ci_lower_limit>
            <ci_upper_limit>10.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis results of ASES total score (PD analysis) at End of Study set)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.804</p_value>
            <method>LS Mean</method>
            <method_desc>LS mean change from baseline in ASES total percentage score</method_desc>
            <param_type>Difference and 90% CI versus placebo</param_type>
            <param_value>1.14</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.50</ci_lower_limit>
            <ci_upper_limit>8.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Your Health Today Score Over Time</title>
        <description>Patient Reported Outcome: Statistical analysis results of EQ-5D-5L for Your health Today questionnaire, which reflects how good or bad the subjets Health is on a scale from 0 (worst health) to 100 (best health).</description>
        <time_frame>Days 15, 29, 57, 85, 99, 127, and End of Study</time_frame>
        <population>PD Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>AIN457 300 mg subcutaneously (s.c.)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c.</description>
          </group>
        </group_list>
        <measure>
          <title>Your Health Today Score Over Time</title>
          <description>Patient Reported Outcome: Statistical analysis results of EQ-5D-5L for Your health Today questionnaire, which reflects how good or bad the subjets Health is on a scale from 0 (worst health) to 100 (best health).</description>
          <population>PD Analysis Set</population>
          <units>Scores on a scale</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" lower_limit="-4.02" upper_limit="3.58"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-4.02" upper_limit="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" lower_limit="-0.71" upper_limit="7.25"/>
                    <measurement group_id="O2" value="3.56" lower_limit="-0.69" upper_limit="7.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" lower_limit="-1.07" upper_limit="7.45"/>
                    <measurement group_id="O2" value="9.02" lower_limit="4.45" upper_limit="13.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.36" lower_limit="2.84" upper_limit="11.89"/>
                    <measurement group_id="O2" value="7.79" lower_limit="2.96" upper_limit="12.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.75" lower_limit="4.13" upper_limit="13.38"/>
                    <measurement group_id="O2" value="10.01" lower_limit="5.09" upper_limit="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.55" lower_limit="5.29" upper_limit="13.80"/>
                    <measurement group_id="O2" value="13.59" lower_limit="9.05" upper_limit="18.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.22" lower_limit="4.84" upper_limit="15.60"/>
                    <measurement group_id="O2" value="12.13" lower_limit="6.36" upper_limit="17.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis results of Your Health Today EQ-5D-5L Index score at day 99 (PD Analysis Set)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.706</p_value>
            <method>LS Mean</method>
            <method_desc>LS Mean change from baseline in Your Health Today Score at day 99</method_desc>
            <param_type>Difference and 90% CI versus placebo</param_type>
            <param_value>-1.26</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.81</ci_lower_limit>
            <ci_upper_limit>4.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis results of Your Health Today EQ-5D-5L Index score at End of Study</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.647</p_value>
            <method>LS Mean</method>
            <method_desc>LS mean change from baseline in Your Health Today score</method_desc>
            <param_type>Difference and 90% CI versus placebo</param_type>
            <param_value>-1.90</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.79</ci_lower_limit>
            <ci_upper_limit>4.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EQ-5D-5L Index Score Over Time</title>
        <description>Patient Reported Outcome: Statistical analysis results of EQ-5D-5L Index score, which contains 5 items to assess Health Status (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression). Overall scores range from 0 to 1 with lower scores representing a higher level of dysfunction.</description>
        <time_frame>Days 15, 29, 57, 85, 99, 127 and End of Study</time_frame>
        <population>PD Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>AIN457 300 mg subcutaneously (s.c.)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c.</description>
          </group>
        </group_list>
        <measure>
          <title>EQ-5D-5L Index Score Over Time</title>
          <description>Patient Reported Outcome: Statistical analysis results of EQ-5D-5L Index score, which contains 5 items to assess Health Status (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression). Overall scores range from 0 to 1 with lower scores representing a higher level of dysfunction.</description>
          <population>PD Analysis Set</population>
          <units>Scores on a scale</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="0.05" upper_limit="0.10"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.01" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="0.07" upper_limit="0.13"/>
                    <measurement group_id="O2" value="0.09" lower_limit="0.05" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="0.09" upper_limit="0.15"/>
                    <measurement group_id="O2" value="0.11" lower_limit="0.08" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" lower_limit="0.13" upper_limit="0.19"/>
                    <measurement group_id="O2" value="0.14" lower_limit="0.10" upper_limit="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" lower_limit="0.13" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.11" upper_limit="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="0.15" upper_limit="0.23"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.13" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="0.16" upper_limit="0.23"/>
                    <measurement group_id="O2" value="0.18" lower_limit="0.14" upper_limit="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis results of of EQ-5D-5L Index score at day 99 (PD Analysis Set)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.613</p_value>
            <method>LS Mean</method>
            <method_desc>LS mean change from baseline in EQ-5D-5L Index score</method_desc>
            <param_type>Difference and 90% CI versus placebo</param_type>
            <param_value>0.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis results of of EQ-5D-5L Index score at End of Study (PD Analysis Set)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.740</p_value>
            <method>LS Mean</method>
            <method_desc>LS mean change from baseline in EQ-5D-5L Index score</method_desc>
            <param_type>Difference and 90% CI versus placebo</param_type>
            <param_value>0.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.04</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score Over Time Using a VAS Scale</title>
        <description>Pain intensity is assessed by a Visual Analog Scale (VAS) which is measured on a 100mm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain&quot;.&#xD;
The scale range for pain score is 0-100, 0 being the best possible outcome (no pain) and 100 being the worst possible outcome (worst pain).</description>
        <time_frame>Days 15, 29, 57, 85, 99, 127 and End of Study</time_frame>
        <population>PD Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>AIN457 300 mg subcutaneously (s.c.)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score Over Time Using a VAS Scale</title>
          <description>Pain intensity is assessed by a Visual Analog Scale (VAS) which is measured on a 100mm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain&quot;.&#xD;
The scale range for pain score is 0-100, 0 being the best possible outcome (no pain) and 100 being the worst possible outcome (worst pain).</description>
          <population>PD Analysis Set</population>
          <units>Scores on a scale</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.11" lower_limit="-19.52" upper_limit="-4.70"/>
                    <measurement group_id="O2" value="-9.50" lower_limit="-17.30" upper_limit="-1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.04" lower_limit="-33.97" upper_limit="-18.11"/>
                    <measurement group_id="O2" value="-23.13" lower_limit="-31.52" upper_limit="-14.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.52" lower_limit="-43.67" upper_limit="-27.37"/>
                    <measurement group_id="O2" value="-32.83" lower_limit="-41.52" upper_limit="-24.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.63" lower_limit="-50.88" upper_limit="-34.38"/>
                    <measurement group_id="O2" value="-37.97" lower_limit="-46.74" upper_limit="-29.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.11" lower_limit="-54.10" upper_limit="-38.12"/>
                    <measurement group_id="O2" value="-40.56" lower_limit="-49.00" upper_limit="-32.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.44" lower_limit="-57.45" upper_limit="-41.44"/>
                    <measurement group_id="O2" value="-45.27" lower_limit="-53.75" upper_limit="-36.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.23" lower_limit="-60.31" upper_limit="-44.14"/>
                    <measurement group_id="O2" value="-50.74" lower_limit="-59.40" upper_limit="-42.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis results of pain score using VAS scale (PD Analysis Set) at day 99</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.281</p_value>
            <method>LS Mean</method>
            <method_desc>LS MMean CFB (90% CI)</method_desc>
            <param_type>Difference and 90% CI versus placebo</param_type>
            <param_value>-5.55</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.07</ci_lower_limit>
            <ci_upper_limit>2.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis results of pain score using VAS scale (PD Analysis Set) at End of Study</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.780</p_value>
            <method>LS Mean</method>
            <method_desc>LS Mean CFB (90% CI)</method_desc>
            <param_type>Difference and 90% CI versus placebo</param_type>
            <param_value>-1.49</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.33</ci_lower_limit>
            <ci_upper_limit>7.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Assessment (PGA) Score Over Time Using a VAS Scale</title>
        <description>The patient's global assessment of disease activity is performed using a 100 mm Visual Analog Scale (VAS) ranging from &quot;no activity&quot; to &quot;most active&quot; in the last 24 hours.&#xD;
The scale range for PGA score is 0-100, 0 being the best possible outcome (no disease activity) and 100 being the worst possible outcome (maximal disease activity).</description>
        <time_frame>Days 15, 29, 57, 85, 99, 127 and End of Study</time_frame>
        <population>PD Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>AIN457 300 mg subcutaneously (s.c.)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment (PGA) Score Over Time Using a VAS Scale</title>
          <description>The patient's global assessment of disease activity is performed using a 100 mm Visual Analog Scale (VAS) ranging from &quot;no activity&quot; to &quot;most active&quot; in the last 24 hours.&#xD;
The scale range for PGA score is 0-100, 0 being the best possible outcome (no disease activity) and 100 being the worst possible outcome (maximal disease activity).</description>
          <population>PD Analysis Set</population>
          <units>Scores on a scale</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.33" lower_limit="-13.44" upper_limit="0.79"/>
                    <measurement group_id="O2" value="-8.09" lower_limit="-15.79" upper_limit="-0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.25" lower_limit="-29.68" upper_limit="-14.82"/>
                    <measurement group_id="O2" value="-16.38" lower_limit="-24.43" upper_limit="-8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.40" lower_limit="-37.06" upper_limit="-21.74"/>
                    <measurement group_id="O2" value="-25.69" lower_limit="-34.04" upper_limit="-17.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.57" lower_limit="-45.01" upper_limit="-30.12"/>
                    <measurement group_id="O2" value="-31.75" lower_limit="-39.79" upper_limit="-23.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.43" lower_limit="-45.88" upper_limit="-30.97"/>
                    <measurement group_id="O2" value="-35.10" lower_limit="-43.14" upper_limit="-27.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.78" lower_limit="-51.23" upper_limit="-36.33"/>
                    <measurement group_id="O2" value="-38.32" lower_limit="-46.37" upper_limit="-30.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.72" lower_limit="-55.15" upper_limit="-40.28"/>
                    <measurement group_id="O2" value="-39.43" lower_limit="-47.45" upper_limit="-31.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis results of pain score using VAS scale (PD Analysis Set) at day 99</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.489</p_value>
            <method>LS Mean</method>
            <method_desc>LS Mean change from baseline in VAS score</method_desc>
            <param_type>Difference and 90% CI versus placebo</param_type>
            <param_value>-3.32</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.28</ci_lower_limit>
            <ci_upper_limit>4.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis results of pain score using VAS scale at End of Study</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.087</p_value>
            <method>LS Mean</method>
            <method_desc>LS Mean change from baseline in VAS score</method_desc>
            <param_type>Difference and 90% CI versus placebo</param_type>
            <param_value>-8.29</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.26</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Global Assessment (PhGA) Score Using a VAS Scale Over Time</title>
        <description>Physician global assessment (PhGA) score using a VAS scale (considering the last 24 hours).&#xD;
The scale range for PhGA score is 0-100, 0 being the best possible outcome (no disease activity) and 100 being the worst possible outcome (maximal disease activity).</description>
        <time_frame>Days 15, 29, 57, 85, 99, 127 and End of Study</time_frame>
        <population>PD Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>AIN457 300 mg subcutaneously (s.c.)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c.</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Assessment (PhGA) Score Using a VAS Scale Over Time</title>
          <description>Physician global assessment (PhGA) score using a VAS scale (considering the last 24 hours).&#xD;
The scale range for PhGA score is 0-100, 0 being the best possible outcome (no disease activity) and 100 being the worst possible outcome (maximal disease activity).</description>
          <population>PD Analysis Set</population>
          <units>Score on a scale</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.99" lower_limit="-20.22" upper_limit="-7.75"/>
                    <measurement group_id="O2" value="-9.11" lower_limit="-15.80" upper_limit="-2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.01" lower_limit="-31.51" upper_limit="-18.50"/>
                    <measurement group_id="O2" value="-19.42" lower_limit="-26.42" upper_limit="-12.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.78" lower_limit="-37.57" upper_limit="-23.99"/>
                    <measurement group_id="O2" value="-27.83" lower_limit="-35.13" upper_limit="-20.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.42" lower_limit="-40.68" upper_limit="-26.16"/>
                    <measurement group_id="O2" value="-37.88" lower_limit="-45.66" upper_limit="-30.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.72" lower_limit="-42.66" upper_limit="-28.79"/>
                    <measurement group_id="O2" value="-41.73" lower_limit="-49.15" upper_limit="-34.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.72" lower_limit="-48.32" upper_limit="-35.12"/>
                    <measurement group_id="O2" value="-44.18" lower_limit="-51.28" upper_limit="-37.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.64" lower_limit="-51.86" upper_limit="-37.41"/>
                    <measurement group_id="O2" value="-44.26" lower_limit="-52.02" upper_limit="-36.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis results of PhGA score using VAS scale at day 99</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.210</p_value>
            <method>LS Mean</method>
            <method_desc>LS Mean CFB (90% CI)</method_desc>
            <param_type>Difference and 99% CL versus placebo</param_type>
            <param_value>6.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.90</ci_lower_limit>
            <ci_upper_limit>13.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis results of PhGA score using VAS scale at End of Study</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.942</p_value>
            <method>LS Mean</method>
            <method_desc>LS Mean CFB (90% CI)</method_desc>
            <param_type>Difference and 90% CI versus placebo</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.86</ci_lower_limit>
            <ci_upper_limit>8.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Cmin</title>
        <description>Mean trough concentrations&#xD;
Cmin is a pharmacokinetics term for the minimum blood plasma concentration reached by a drug prior to administration of a second dose (mass/volume)&#xD;
Serum trough concentrations of secukinumab 300 mg group was measured at Days 1, 29, 85 and EoS</description>
        <time_frame>Days 1, 29, 85 and EoS (End of Study)</time_frame>
        <population>PD Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>AIN457 300 mg subcutaneously (s.c.)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Cmin</title>
          <description>Mean trough concentrations&#xD;
Cmin is a pharmacokinetics term for the minimum blood plasma concentration reached by a drug prior to administration of a second dose (mass/volume)&#xD;
Serum trough concentrations of secukinumab 300 mg group was measured at Days 1, 29, 85 and EoS</description>
          <population>PD Analysis Set</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean trough concentration after first 4 wkly doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.4" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Assessment - Treatment Emergent ADAs</title>
        <description>Number of Participants with Treatment emergent Anti-secukinumab antibodies</description>
        <time_frame>Day 1 and EoS</time_frame>
        <population>PD Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>AIN457 300 mg subcutaneously (s.c.)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Assessment - Treatment Emergent ADAs</title>
          <description>Number of Participants with Treatment emergent Anti-secukinumab antibodies</description>
          <population>PD Analysis Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Tendinosis Grade Score 1, 2 or 3 Measured by Magnetic Resonance Imaging (MRI) Sein Scores</title>
        <description>Assessment of structural changes in the rotator cuff tendinopathy over time&#xD;
The MRI Sein score was used to grade supraspinatus tendinosis using a modified 4-point scale from 0 to 3 and changes in grading over time were captured in the shift table. Grade 0 is normal, grade 1 is mild, Grade 2 is moderate and grade 3 is marked tendinosis.&#xD;
In this Sein score assessment, only data from Day 99 and baseline could be compared, as only those two time points were double read and adjudicated in case the 2 readers had different results. At any other time-points (Day 57 and EOS), images were assessed only by one reader and thus could not be compared to baseline.</description>
        <time_frame>Baseline and Day 99</time_frame>
        <population>PD Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>AIN457 300 mg subcutaneously (s.c.)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Tendinosis Grade Score 1, 2 or 3 Measured by Magnetic Resonance Imaging (MRI) Sein Scores</title>
          <description>Assessment of structural changes in the rotator cuff tendinopathy over time&#xD;
The MRI Sein score was used to grade supraspinatus tendinosis using a modified 4-point scale from 0 to 3 and changes in grading over time were captured in the shift table. Grade 0 is normal, grade 1 is mild, Grade 2 is moderate and grade 3 is marked tendinosis.&#xD;
In this Sein score assessment, only data from Day 99 and baseline could be compared, as only those two time points were double read and adjudicated in case the 2 readers had different results. At any other time-points (Day 57 and EOS), images were assessed only by one reader and thus could not be compared to baseline.</description>
          <population>PD Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99 grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99 grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99 grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 40 weeks: 15 Dec 2017 through 17 Oct 2019</time_frame>
      <desc>Adverse Events (AEs) are any untoward sign or symptom that occurs during the study treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>AIN457 300 mg s.c.</title>
          <description>AIN457 300 mg</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo s.c.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Faeces soft</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Injection site paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pustule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Injection related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Red blood cell sedimentation rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Patellofemoral pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign bone neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Phonophobia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Keratolysis exfoliativa acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In general &quot;End of Study&quot; is Day 169 (week 24). But in the study it was handled in a way, that whenever a subject discontinued the last visit was the EoS visit.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>+1 (862) 778-8300</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

